Results 21 to 30 of about 294,417 (155)
Molecular & Cellular Oncology, 2020 The oncoprotein transcription factor MYC is overexpressed in most cancers and is responsible for hundreds of thousands of cancer deaths worldwide every year. MYC is also a highly validated – but currently undruggable – anti-cancer target.
Lance R. Thomas +4 more
doaj +1 more source
Involvement of Myc targets in c-myc and N-myc induced human tumors [PDF]
Oncogene, 1998 The myc proto-oncogenes are transcription factors that directly regulate the expression of other genes, by binding to the specific DNA sequence, CACGTG. Among the target genes for c-Myc regulation are ECA39, p53, ornithine decarboxylase (ODC), alpha-prothymosin and Cdc25A.
T, Ben-Yosef +3 more
openaire +2 more sources
The Molecular ‘Myc-anisms’ behind Myc-Driven Tumorigenesis and the Relevant Myc-Directed Therapeutics [PDF]
International Journal of Molecular Sciences, 2020 MYC, a well-studied proto-oncogene that is overexpressed in >20% of tumors across all cancers, is classically known as “undruggable” due to its crucial roles in cell processes and its lack of a drug binding pocket. Four decades of research and creativity led to the discovery of a myriad of indirect (and now some direct!) therapeutic strategies ...
Jessica McAnulty, Analisa DiFeo
openaire +2 more sources
Клиническая онкогематология, 2022 Background. Plasmablastic lymphoma (PBL) is a rare lymphoproliferative disease which is almost exclusively associated with immunodeficiency. Most ample experience of chemotherapy and hematopoietic stem cells transplantation (HSCT) in this lymphoma ...
Marina Olegovna Popova +19 more
doaj +1 more source
Genome Recognition by MYC [PDF]
Cold Spring Harbor Perspectives in Medicine, 2014 MYC dimerizes with MAX to bind DNA, with a preference for the E-box consensus CACGTG and several variant motifs. In cells, MYC binds DNA preferentially within transcriptionally active promoter regions. Although several thousand promoters are bound under physiological (low MYC) conditions, these represent only a fraction of all accessible, active ...
A. Sabo, B. Amati
openaire +2 more sources
Drug Design, Development and Therapy, 2021 Dongfang Tang,1 Tao Huang,2 Qilong Tian,2 Julei Wang2 1Department of Neurosurgery, Henan Provincial People’s Hospital, Central China Fuwai Hospital, Central China Fuwai Hospital of Zhengzhou University, Zhengzhou, People’s Republic of China ...
Tang D, Huang T, Tian Q, Wang J
doaj
Targeting mutagenesis in B cells: Phosphorylation goes beyond AID association
Molecular & Cellular Oncology, 2018 The mutations induced by activation-induced cytidine deaminase (AID) trigger antibody diversification but can cause genome instability. We find that AID phosphorylation is an important determinant of “off-target” mutagenesis and identify a drug that ...
Yunxiang Mu, Kevin M. McBride
doaj +1 more source
Tuning protein synthesis for cancer therapy
Molecular & Cellular Oncology, 2021 ~50% of colorectal cancers have an activating mutation in KRAS (encoding the KRAS proto-oncogene) and remain difficult to target in the clinic. We have recently shown that activation of KRAS protein alters the regulation of mRNA translation, increasing ...
John R. P. Knight, Owen J. Sansom
doaj +1 more source
Chromatin Immunoprecipitation Assays for Myc and N-Myc [PDF]
, 2013 Myc and N-Myc have widespread impacts on the chromatin state within cells, both in a gene-specific and genome-wide manner. Our laboratory uses functional genomic methods including chromatin immunoprecipitation (ChIP), ChIP-chip, and, more recently, ChIP-seq to analyze the binding and genomic location of Myc.
Bonnie L, Barrilleaux +2 more
openaire +2 more sources
The Role of MYC and PP2A in the Initiation and Progression of Myeloid Leukemias
Cells, 2020 The MYC transcription factor is one of the best characterized PP2A substrates. Deregulation of the MYC oncogene, along with inactivation of PP2A, are two frequent events in cancer.
Raffaella Pippa, Maria D. Odero
doaj +1 more source